Health insurers are praising a provision in a recently proposed regulation that gives commercial plans greater leeway to run so-called copay accumulator programs, which prevent drug manufacturer coupons from counting toward patients’ annual deductibles or out-of-pocket cost limits. But the pharmaceutical industry slammed the proposal as “misguided” and liable to prevent patients from getting vital medications.
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits
- Headlines in the News
- Abstract, Medicare and Medicaid